Business Context and Reporting Period
This Form 8-K filing by Vir Biotechnology, Inc. (VIR) reports a material event occurring on March 31, 2021. The company is a biotechnology firm incorporated in Delaware and listed on the Nasdaq Global Select Market.
Key Financial Metrics
The filing details a specific equity transaction rather than periodic financial performance metrics such as revenue or operating cash flow.
- Transaction Type: Private placement of common stock.
- Investor: Glaxo Group Limited (GGL), an affiliate of Glaxo Wellcome UK Limited.
- Shares Sold: 1,924,927 shares.
- Price Per Share: $62.34.
- Aggregate Proceeds: Approximately $120.0 million.
Material Changes
The primary material change is the increase in the company's cash position and share count resulting from the closed transaction. The closing was contingent upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, which occurred on March 24, 2021. This transaction was executed pursuant to a stock purchase agreement dated February 14, 2021.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory conditions for the transaction. The document confirms the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the dilution impact of the 1,924,927 newly issued shares on existing shareholders.
- Confirm the use of the approximately $120.0 million in proceeds in subsequent filings (e.g., 10-Q or 10-K).
- Review the February 19, 2021 Form 8-K for the original terms of the stock purchase agreement with GGL.
- Check for any lock-up agreements or restrictions on the shares sold to GGL.